RecruitingNCT02038127

Gangwon PCI Prospective Registry

Prospective Registry for Patients Undergoing Coronary Angiography and Percutaneous Coronary Intervention in Gangwon Province


Sponsor

Yonsei University

Enrollment

5,000 participants

Start Date

Jan 1, 2013

Study Type

OBSERVATIONAL

Conditions

Summary

Comparison of * Biolimus-eluting stent, Biomatrix, or Biomatrix Flex stent, Biosensors, Singapore * Everolimus-eluting stent, Xience V, or Xience Prime, or Xience Xpedition stent, Abbott, USA * Zotarolimus-eluting stent, Endeavor Resolute, or Endeavor Resolute Integrity stent Medtronic, USA in patients with coronary artery disease treated with percutaneous coronary intervention


Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with coronary artery disease. The study is currently recruiting participants at 3 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(3)

Chuncheon Hallym University Hospital

Chuncheon, Gangwon-do, South Korea

Yonsei University Wonju Christian Hospital

Wŏnju, Gangwon-do, South Korea

Korea University Guro Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02038127


Related Trials